Pliant Therapeutics Inc (PLRX) Stock Price, Quote & News

Latest News on PLRX

Apr 7, 2025, 4:05 PM EDT - 13 days ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

Apr 3, 2025, 12:22 PM EDT - 18 days ago

Pliant Therapeutics: An Activist On Deck

$Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Mar 17, 2025, 8:00 AM EDT - 5 weeks ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Mar 13, 2025, 11:04 AM EDT - 5 weeks ago

SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Pliant Therapeutics

Mar 13, 2025, 7:20 AM EDT - 5 weeks ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 3, 2025, 4:05 PM EST - 6 weeks ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 1:32 PM EST - 6 weeks ago

Pliant Therapeutics Stock Sinks, Discontinues Mid-Stage Study For Lung Disorder

Mar 3, 2025, 9:27 AM EST - 7 weeks ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Mar 2, 2025, 11:00 AM EST - 7 weeks ago

The Schall Law Firm Invites Shareholders With Losses In Pliant Therapeutics, Inc. To Join A Securities Fraud Investigation

Feb 27, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Shareholders to Inquire about Securities Investigation

Feb 26, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Connect

Feb 25, 2025, 10:00 AM EST - 7 weeks ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Shareholders to Reach Out

Feb 24, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Shareholders to Learn More About the Investigation

Feb 23, 2025, 10:00 AM EST - 2 months ago

Pliant Therapeutics, Inc. (PLRX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation

Feb 21, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Connect

Feb 20, 2025, 3:39 PM EST - 2 months ago

PLRX Investors Have Opportunity to Join Pliant Therapeutics, Inc. Fraud Investigation with the Schall Law Firm

Feb 20, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Stockholders to Inquire about Securities Investigation

Feb 19, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Investors to Learn More About the Investigation

Feb 18, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Pliant Therapeutics, Inc. (PLRX) and Encourages Stockholders to Learn More About the Investigation

Feb 17, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Encourages Pliant Therapeutics, Inc. (PLRX) Investors to Inquire about Securities Investigation

Feb 16, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Investors to Reach Out

Feb 14, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Reach Out

Feb 13, 2025, 10:00 AM EST - 2 months ago

Bronstein, Gewirtz & Grossman, LLC Is Investigating Pliant Therapeutics, Inc. (PLRX) And Encourages Stockholders to Connect

Feb 13, 2025, 8:00 AM EST - 2 months ago

Pliant Therapeutics Announces Next Steps Following DSMB Recommendation on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

Feb 12, 2025, 4:52 PM EST - 2 months ago

Market Cap	89.62M
Revenue (ttm)	0.00
Net Income (ttm)	-210.30M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.10

Volume	758,100
Avg Vol	3,272,066
Day's Range	N/A - N/A
Shares Out	61.39M
Stochastic %K	89%
Beta	1.46
Analysts	Sell
Price Target	$5.44